## **Sharon Elad**

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3891982/publications.pdf

Version: 2024-02-01

71532 76196 6,192 92 40 76 citations h-index g-index papers 97 97 97 4815 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, 120, 1453-1461.	2.0	838
2	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2020, 126, 4423-4431.	2.0	540
3	Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. Supportive Care in Cancer, 2019, 27, 3969-3983.	1.0	213
4	Systematic review of basic oral care for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 2013, 21, 3165-3177.	1.0	194
5	Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 2013, 21, 333-341.	1.0	193
6	Oral mucositis. Oral Oncology, 2010, 46, 452-456.	0.8	182
7	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biology of Blood and Marrow Transplantation, 2015, 21, 1167-1187.	2.0	182
8	Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations. Supportive Care in Cancer, 2016, 24, 2781-2792.	1.0	179
9	Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Supportive Care in Cancer, 2013, 21, 313-326.	1.0	177
10	Low-level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols. Supportive Care in Cancer, 2016, 24, 2793-2805.	1.0	169
11	Bisphosphonate-Related Osteonecrosis of the Jaws: A Single-Center Study of 101 Patients. Journal of Oral and Maxillofacial Surgery, 2009, 67, 850-855.	0.5	158
12	Basic oral care for hematology–oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Supportive Care in Cancer, 2015, 23, 223-236.	1.0	152
13	Emerging evidence on the pathobiology of mucositis. Supportive Care in Cancer, 2013, 21, 3233-3241.	1.0	145
14	Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 2013, 21, 3191-3207.	1.0	137
15	Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. Supportive Care in Cancer, 2019, 27, 3949-3967.	1.0	127
16	Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Supportive Care in Cancer, 2013, 21, 327-332.	1.0	113
17	Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 2013, 21, 343-355.	1.0	111
18	Systematic review of natural agents for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 2013, 21, 3209-3221.	1.0	95

#	Article	IF	Citations
19	Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 2013, 21, 3179-3189.	1.0	95
20	Systematic review of amifostine for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 2013, 21, 357-364.	1.0	89
21	Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Supportive Care in Cancer, 2019, 27, 383-394.	1.0	85
22	Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients and clinical practice guidelines. Supportive Care in Cancer, 2019, 27, 3985-3995.	1.0	76
23	Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis. Supportive Care in Cancer, 2006, 14, 528-532.	1.0	73
24	A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridea. Supportive Care in Cancer, 2010, 18, 993-1006.	1.0	68
25	Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: A multicenter, randomized trial. Arthritis and Rheumatism, 2011, 63, 180-190.	6.7	67
26	Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD. Clinical Oral Investigations, 2011, 15, 127-139.	1.4	65
27	A decision analysis: The dental management of patients prior to hematology cytotoxic therapy or hematopoietic stem cell transplantation. Oral Oncology, 2008, 44, 37-42.	0.8	63
28	Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Cancer Medicine, 2016, 5, 1897-1907.	1.3	62
29	Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines. Supportive Care in Cancer, 2020, 28, 2449-2456.	1.0	60
30	The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies. Ca-A Cancer Journal for Clinicians, 2022, 72, 57-77.	157.7	60
31	Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelinesâ€"part 1: vitamins, minerals, and nutritional supplements. Supportive Care in Cancer, 2019, 27, 3997-4010.	1.0	54
32	Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines â€" part 2: honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents. Supportive Care in Cancer, 2020, 28, 2457-2472.	1.0	54
33	Oral Trauma and Tooth Avulsion Following Explosion of E-Cigarette. Journal of Oral and Maxillofacial Surgery, 2016, 74, 1181-1185.	0.5	52
34	Intraoral electrostimulator for xerostomia relief: a long-term, multicenter, open-label, uncontrolled, clinical trial. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2012, 113, 773-781.	0.2	51
35	Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. Supportive Care in Cancer, 2019, 27, 4011-4022.	1.0	51
36	Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 2013, 21, 3223-3232.	1.0	50

3

#	Article	IF	CITATIONS
37	The cardiovascular effect of local anesthesia with articaine plus 1:200,000 adrenalin versus lidocaine plus 1:100,000 adrenalin in medically compromised cardiac patients: a prospective, randomized, double blinded study. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2008, 105, 725-730.	1.6	49
38	Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines. Supportive Care in Cancer, 2020, 28, 2473-2484.	1.0	46
39	Time limitations and the challenge of providing infection-preventing dental care to hematopoietic stem-cell transplantation patients. Supportive Care in Cancer, 2003, 11, 674-677.	1.0	45
40	Chronic oral mucositis after radiotherapy to the head and neck: a new insight. Supportive Care in Cancer, 2016, 24, 4825-4830.	1.0	45
41	Budesonide: A novel treatment for oral chronic graft versus host disease. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2003, 95, 308-311.	1.6	43
42	Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines. Supportive Care in Cancer, 2020, 28, 2485-2498.	1.0	42
43	A Survey of the Current Approaches to Diagnosis and Management of Oral Premalignant Lesions. Journal of the American Dental Association, 2007, 138, 1555-1562.	0.7	36
44	Bisphosphonate-related osteonecrosis of the jaw: clinical correlations with computerized tomography presentation. Clinical Oral Investigations, 2010, 14, 43-50.	1.4	35
45	Oral Complications of Nonsurgical Cancer Therapies. Atlas of the Oral and Maxillofacial Surgery Clinics of North America, 2017, 25, 133-147.	0.4	33
46	MASCC/ISOO clinical practice guidelines for the management of mucositis: sub-analysis of current interventions for the management of oral mucositis in pediatric cancer patients. Supportive Care in Cancer, 2021, 29, 3539-3562.	1.0	33
47	Development of the MASCC/ISOO clinical practice guidelines for mucositis: an overview of the methods. Supportive Care in Cancer, 2019, 27, 3933-3948.	1.0	32
48	Osteonecrosis of the jaws induced by drugs other than bisphosphonates $\hat{a} \in A$ call to update terminology in light of new data. Oral Oncology, 2010, 46, e1.	0.8	31
49	Cytotoxic Chemotherapy-induced Odontalgia: A Differential Diagnosis for Dental Pain. Journal of Endodontics, 2010, 36, 1588-1592.	1.4	31
50	The antimicrobial effect of Iseganan HCl oral solution in patients receiving stomatotoxic chemotherapy: analysis from a multicenter, doubleâ€blind, placeboâ€controlled, randomized, phase III clinical trial. Journal of Oral Pathology and Medicine, 2012, 41, 229-234.	1.4	30
51	Development of the MASCC/ISOO Clinical Practice Guidelines for Mucositis: considerations underlying the process. Supportive Care in Cancer, 2013, 21, 309-312.	1.0	30
52	Validation of The National Institutes of Health (NIH) Scale for Oral Chronic Graft-versus-Host Disease (cGVHD). Biology of Blood and Marrow Transplantation, 2010, 16, 62-69.	2.0	28
53	Ultraviolet B irradiation: A new therapeutic concept for the management of oral manifestations of graft-versus-host disease. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 1999, 88, 444-450.	1.6	27
54	Photobiomodulation therapy in the management of oral mucositis: search for the optimal clinical treatment parameters. Supportive Care in Cancer, 2018, 26, 3319-3321.	1.0	27

#	Article	IF	CITATIONS
55	Chronic graftâ€versusâ€host disease: Current management paradigm and future perspectives. Oral Diseases, 2019, 25, 931-948.	1.5	26
56	Oral posttransplantation lymphoproliferative disorder: an uncommon site for an uncommon disorder. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2008, 105, 59-64.	1.6	25
57	Oral Cancer in Patients After Hematopoietic Stem-Cell Transplantation: Long-Term Follow-Up Suggests an Increased Risk for Recurrence. Transplantation, 2010, 90, 1243-1244.	0.5	25
58	Exceptional oral manifestations of amyloid light chain protein (AL) systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2010, 17, 27-31.	1.4	24
59	Improvement in Oral Chronic Graft-versus-Host Disease with the Administration of Effervescent Tablets of Topical Budesonide—An Open, Randomized, Multicenter Study. Biology of Blood and Marrow Transplantation, 2012, 18, 134-140.	2.0	24
60	Treatment of oral mucosal manifestations of chronic graft-versus-host disease: dexamethasone vs. budesonide. Expert Opinion on Pharmacotherapy, 2017, 18, 235-242.	0.9	23
61	Saliva Secretion in Patients with Allergic Rhinitis. International Archives of Allergy and Immunology, 2006, 141, 276-280.	0.9	22
62	A randomized controlled trial of visible-light therapy for the prevention of oral mucositis. Oral Oncology, 2011, 47, 125-130.	0.8	22
63	Oral mucosal changes associated with primary diseases in other body systems. Periodontology 2000, 2019, 80, 28-48.	6.3	20
64	Photobiomodulation Therapy for Cancer Treatment-Related Salivary Gland Dysfunction: A Systematic Review. Photobiomodulation, Photomedicine, and Laser Surgery, 2020, 38, 340-347.	0.7	20
65	The MASCC/ISOO mucositis guidelines 2019: the second set of articles and future directions. Supportive Care in Cancer, 2020, 28, 2445-2447.	1.0	19
66	Topical immunomodulators for management of oral mucosal conditions, a systematic review; part I: calcineurin inhibitors. Expert Opinion on Emerging Drugs, 2010, 15, 713-726.	1.0	18
67	Oral Graft-Versus-Host Disease: A Pictorial Review and a Guide for Dental Practitioners. International Dental Journal, 2021, 71, 9-20.	1.0	17
68	Topical curcumin for the prevention of oral mucositis in pediatric patients: case series. Alternative Therapies in Health and Medicine, 2013, 19, 21-4.	0.0	16
69	Oral Manifestations of Systemic Diseases. Dermatologic Clinics, 2020, 38, 495-505.	1.0	15
70	The Search for an Effective Therapy and Pain Relief for Oral Mucositis. JAMA - Journal of the American Medical Association, 2019, 321, 1459.	3.8	14
71	Budesonide for local therapy of complex oral mucosal immune-mediated inflammatory diseases: case reports. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2008, 106, e11-e17.	1.6	13
72	Clinical approach in the management of oral chronic graft-versus-host disease (cGVHD) in a series of specialized medical centers. Supportive Care in Cancer, 2015, 23, 1615-1622.	1.0	13

#	Article	IF	CITATIONS
73	A systematic review of oral herpetic viral infections in cancer patients: commonly used outcome measures and interventions. Supportive Care in Cancer, 2017, 25, 687-700.	1.0	13
74	The MASCC/ISOO Mucositis Guidelines 2019 Update: introduction to the first set of articles. Supportive Care in Cancer, 2019, 27, 3929-3931.	1.0	13
75	A new management approach for dental treatment after a cerebrovascular event: a comparative retrospective study. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2010, 110, 145-150.	1.6	12
76	Oral candidiasis prevention in transplantation patients: a comparative study. Clinical Transplantation, 2006, 20, 318-324.	0.8	11
77	Economic and Practical Considerations in the Treatment of Oral Mucosal Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 1748-1753.	2.0	9
78	Safety and efficacy of an intra-oral electrostimulator for the relief of dry mouth in patients with chronic graft versus host disease: Case Series. Medicina Oral, Patologia Oral Y Cirugia Bucal, 2014, 19, e212-e219.	0.7	7
79	Oral Bisphosphonate-Related Osteonecrosis of the Jaw: Incidence, Clinical Features, Prevention, and Treatment Recommendations. Clinical Reviews in Bone and Mineral Metabolism, 2010, 8, 27-31.	1.3	6
80	Topical budesonide for severe oral chronic graft-versus-host disease. American Journal of Health-System Pharmacy, 2014, 71, 181-182.	0.5	6
81	Oral lichenoid reactions may possibly be associated with abatacept: A case report and literature update. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2018, 126, e245-e251.	0.2	5
82	Oral verruciform xanthoma in chronic graft-versus-host disease patients. Supportive Care in Cancer, 2021, 29, 79-84.	1.0	5
83	The impact of the COVID-19 outbreak on supportive care for oral mucositis: current concepts and practice. Supportive Care in Cancer, 2021, 29, 2255-2258.	1.0	5
84	Oral white lesion in patients post-hematopoietic stem cell transplantation: a case series demonstrating the diagnostic dilemma. Supportive Care in Cancer, 2021, 29, 7999-8007.	1.0	3
85	Survey of acceptance of the 2007 American Heart Association guidelines for the prevention of infective endocarditis: a pilot study. Quintessence International, 2011, 42, 243-51.	0.3	3
86	Confounding factors in the assessment of oral mucositis in head and neck cancer. Supportive Care in Cancer, 2022, 30, 8455-8463.	1.0	3
87	Cost-effective analysis of topical chlorhexidine in hematologic patients at risk for oral mucositis. Clinical Oral Investigations, 2015, 19, 1843-1850.	1.4	2
88	Orofacial Pain in Patients with Cancer and Mucosal Diseases. , 2019, , 2187-2212.		2
89	Orofacial Pain in Patients with Cancer and Mucosal Diseases. , 2018, , 1-27.		2
90	Oral effects of nonmyeloablative stem cell transplantation: a prospective observational study. Quintessence International, 2008, 39, 673-8.	0.3	2

#	Article	IF	CITATIONS
91	Bisphosphonate-Related Osteonecrosis of the Jaw. Journal of the American Dental Association, 2016, 147, 776-777.	0.7	1
92	Duration to Engraftment Requires Significantly Much More Time in Myelodysplastic Syndrome (MDS) Patients as Compared to Acute Myeloid Leukemia (AML) Patients Following Allogeneic Stem Cell Transplantation Blood, 2005, 106, 5326-5326.	0.6	0